准分子通路以控制免疫检查点抑制剂毒性
Robin Reschke1, Ryan J Sullivan2, Evan J Lipson3
1Heidelberg University, Medical Faculty Heidelberg, Department of Dermatology and National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and University Hospital Heidelberg, Heidelberg, Germany; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) Core Center Heidelberg, 69120 Heidelberg, Germany.
免疫检查点抑制剂 (ICI) 对抗癌症,但会引起与免疫相关的不良事件 (irAEs). 了解涉及免疫细胞,细胞因子和微生物组的irAE机制,可以提供新的策略来减轻这些副作用,同时保持癌症治疗的疗效.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 免疫检查点抑制剂 (ICI) 已经彻底改变了癌症治疗.
- 与免疫相关的不良事件 (irAEs) 是常见的,可以影响多个器官系统.
- 需要进一步阐明irAEs的分子基础.
研究的目的:
- 综合关于irAEs分子机制的临床前和临床发现.
- 为了识别关键的免疫细胞,信号通路和参与irAE病变的因素.
- 探索新的治疗策略,以减轻irAEs,同时保持ICI的疗效.
主要方法:
- 关于irAEs的临床前和临床研究的全面审查.
- 在irAE发育中分析免疫细胞子集 (T细胞,髓状细胞).
- 检查细胞因子信号传递 (例如IL-6,IFN-γ,TNF-α),整合素相互作用和微生物群的影响.
主要成果:
- T细胞子集和骨髓状细胞在irAE病变发生过程中发挥着关键作用.
- 特定的细胞因子信号通路 (IL-6,IL-17,IL-4,IFN-γ,IL-1β,TNF-α) 参与了irAEs.
- 集成因子介导的相互作用和微生物组失生症对irAE病理学有显著的贡献.
结论:
- 了解irAE分子驱动因素为有针对性的缓解策略提供了机会.
- 针对关键炎症分子的抗体可能会减少irAEs.
- 治疗干预应旨在平衡irAE管理与持续的ICI抗瘤活性.
更多相关视频
09:01Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
相关概念视频
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
